Antimicrobial Susceptibility Testing Market Size
The global antimicrobial susceptibility testing market was valued at USD 4.18 billion in 2025 and is estimated to reach USD 8.16 billion by 2033, growing at a CAGR of 8.5% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by the rising prevalence of infectious diseases and the increasing threat of antimicrobial resistance worldwide.
Market growth is primarily fueled by the growing need for accurate and rapid diagnostic solutions to guide effective antibiotic therapy. The increasing incidence of hospital-acquired infections and the rising demand for personalized treatment approaches are further accelerating market expansion. Additionally, supportive government initiatives and global efforts to combat antimicrobial resistance are contributing to increased adoption of advanced testing technologies.
Antimicrobial susceptibility testing plays a critical role in determining the effectiveness of antibiotics against specific pathogens, enabling clinicians to select appropriate treatment strategies. These systems are widely used in hospitals, diagnostic laboratories, and research institutions for infection control and surveillance. Continuous advancements in automated testing systems, molecular diagnostics, and rapid testing methods are enhancing accuracy and turnaround time. With increasing focus on patient safety, precision medicine, and infection control, the antimicrobial susceptibility testing market is becoming an essential component of the global healthcare diagnostics ecosystem.
Antimicrobial Susceptibility Testing Market Summary
| Metrics | Details |
| Market CAGR | 8.5 % |
| Segments Covered | By Product Type, By Method, By Test Type, By Application, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights about the Market Request free Sample
Antimicrobial Susceptibility Testing Market Dynamics
The global antimicrobial susceptibility testing market growth is driven by technological advancement, a rising prevalence of infectious disease, rising funding for research and development from government and private organizations, and advancements in healthcare infrastructure.
The rising need for antimicrobial susceptibility testing across the globe drives the market growth
Antimicrobial resistance (AMR) has appeared as a major threat to public health worldwide. According to the World Health Organization (WHO), antibiotic resistance is rising to dangerously high levels in all regions of the world, leading to raised morbidity and mortality. In addition, the World Bank estimates that drug-resistant infections could induce a global economic crisis, leading to 28 million people who could be moved into extreme poverty every year by 2050, with an overall cost to the global economy of USD 1 trillion per year.
Exact and quick detection of resistance to antimicrobial drugs and following appropriate antimicrobial treatment, incorporated with antimicrobial stewardship, are crucial for controlling the emergence and spread of AMR. The best therapeutic option for treating bacterial infections relies on the results of AST, a part of the routine work of all clinical microbiological laboratories. Reports provide an understanding of local antimicrobial susceptibility patterns, helping healthcare professionals select the most effective antibiotic therapy. For instance, if the AMR rate of a pathogen is above 20%, that drug should not be administered as a single empiric therapy for infection treatment.
In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in April 2022, BIOMÉRIEUX agreed to acquire Specific Diagnostics. This privately held U.S.-based company has developed a rapid antimicrobial susceptibility test (AST), SPECIFIC REVEAL Rapid AST system that delivers phenotypic AST directly from positive blood cultures. Moreover, in February 2020, Bio-Rad Laboratories, Inc. acquired Exact Diagnostics, a developer and manufacturer of diagnostic products that help ensure the validity and consistency of test results. With the acquisition of Exact Diagnostics, Bio-Rad Laboratories, Inc. has access to a comprehensive catalog of molecular quality control products in transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.
The drawbacks of antimicrobial susceptibility testing products/instruments will hamper the growth of the market
However, besides high costs, major drawbacks of molecular methods are the detection of the resistance genes targeted only by the available probes and overestimating resistance because the resistance gene is not necessarily associated with the expression of a resistance phenotype. In addition, automated and semi-automated systems have inherent advantages and limitations, and the results vary widely by antimicrobial drugs, software versions, and cards. Hence, some systems are unreliable for correctly categorizing susceptibility profiles for certain drugs, leading to wrong classifications of susceptibility categories. It appears that small inoculum size significantly influences the outcome of these systems, with false susceptibilities being reported.
Recent Developments
February 2026: In North America, particularly the United States, rising incidence of infectious diseases and increasing antimicrobial resistance significantly accelerated adoption of AST adoption, supported by strong regulatory frameworks and widespread use of automated diagnostic systems in hospitals and laboratories.
January 2026: In Europe, countries such as Germany, France, and the United Kingdom strengthened public health initiatives and antimicrobial stewardship programs, driving demand for advanced resistance monitoring solutions to ensure accurate antibiotic selection and regulatory compliance.
December 2025: In Asia Pacific, especially China, India, and Japan, rapid expansion of healthcare infrastructure, increasing clinical testing volumes, and rising awareness of drug-resistant infections positioned the region as the fastest-growing market for diagnostic growth and susceptibility testing solutions.
November 2025: In the Middle East & Africa, growing investments in healthcare systems and increasing focus on infectious disease control supported gradual adoption of antimicrobial susceptibility testing technologies, boosting healthcare expansion across emerging economies.
October 2025: Globally, rapid advancements in automation, artificial intelligence, and genomic-based testing significantly enhanced speed and accuracy of diagnostics, enabling real-time decision-making and highlighting technology innovation in susceptibility testing platforms.
September 2025: Across global markets, increasing shift toward rapid and point-of-care testing solutions gained strong momentum, reducing turnaround time and improving patient outcomes, thereby accelerating rapid testing adoption in clinical settings.
The market is rapidly evolving toward intelligent, automated, and precision-driven diagnostic ecosystems, with strong growth driven by rising antimicrobial resistance, increasing demand for rapid diagnostics, and continuous advancements in AI-powered and genomic testing technologies, positioning antimicrobial susceptibility testing as a critical pillar in modern infectious disease management and global healthcare systems.
Antimicrobial Susceptibility Testing Market Segment Analysis
The automated laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2026-2033)
By Product Type:
- Susceptibility Testing Disks
- MIC Strips
- Susceptibility Plates
- Automated Laboratory Instruments
- Consumables
By Method:
- Broth Dilution Method
- Rapid Automated Method
- Disk Diffusion Method
- Gradient Diffusion Method
- Molecular Testing Method
By Test Type:
- Antibacterial
- Antifungal
- Antiparasitics
- Others
By Application:
- Clinical Diagnosis
- Drug Discovery and Development
- Others
By End-User:
- Diagnostic Centers and Hospitals
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations (CROs)
- Research and Academic Institutes
The automated laboratory instruments segment accounts for the largest market share. As per the article published in Antibiotics Journal in 2022, current technologies for rapid AST are available in the market, including automated and semi-automated devices based on microdilution susceptibility testing. For instance, the Phoenix System is widely accepted and used in clinical microbiology laboratories for identification and antimicrobial susceptibility testing. The principle of determining the susceptibility is based on using an oxidation-reduction indicator (Alamar blue or resazurin dye) and detecting bacterial growth in the presence of various concentrations of the antimicrobial agent. Also, The MicroScan WalkAway plus System provides accurate and rapid identification and susceptibility results for a wide range of Grampositive and Gram-negative aerobic bacteria.
In addition, The first generation of the MicroScan WalkAway System available on the market is the AutoSCAN-3. The new versions of instruments Auto-ACAN-4 and AutoSCAN-WalkAway are improved and use dry panels that do not need refrigeration. The AutoSCAN-WalkAway system detects bacterial enzymatic activity and can process 96 panels simultaneously. The availability of advanced and automated systems for AST boosts the market worldwide.
Antimicrobial Susceptibility Testing Market Geographical Share
North America region holds the largest market share of the global Antimicrobial Susceptibility Testing market
North America dominates the market for antimicrobial susceptibility testing and is expected to show a similar trend over the forecast period. The growth of the North American antimicrobial susceptibility testing market can be attributed to technological advancements, rising infectious disease, increasing launching of products and the presence of key players.
According to the bioMérieux organization, more than 2.8 million antibiotic-resistant infections occur annually in the United States. The emergence of resistant bacteria is an unpretending phenomenon worsened and accelerated by the improper use of antibiotics. Rising antimicrobial susceptibility testing in the region drives the market.
In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in May 2022, Accelerate Diagnostics, Inc. announced the commercialization of its new Accelerate Arc Module and BC kit. The Accelerate Arc Module and BC kit is a new application of inline centrifugation and automated sample prep techniques, which, together with the blood culture kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. In addition, Accelerate PhenoTest BC kit AST configuration enables laboratories to report identification and antimicrobial susceptibility test results directly from positive blood cultures days earlier than current standard-of-care methods.
Antimicrobial Susceptibility Testing Companies and Competitive Landscape
The antimicrobial susceptibility testing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are bioMérieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, and Synbiosis, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global antimicrobial susceptibility testing market.
bioMérieux SA
Overview:
bioMérieux SA is an organization that provides solutions for microbiology, which is used in clinical labs to provide effective results because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.
Product Portfolio:
VITEK 2: It is an automated susceptibility testing system capable of determining the extensive majority of routine organisms (around 300 microorganisms). This system gives results within hours due to the combination of analysis software and an original, miniaturized consumable. This testing system is available for a various range of microorganisms.
The global antimicrobial susceptibility testing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
